Biotechnology in Israel

Dr. Golik

Dr. Golik is a leading supplier of advance scientific instrumentation, technical service and application support that apply advanced technologies for accurate analysis and characterization of: chemical ions, particles, GPC, zeta potential, powdered and porous materials properties etc. We supply solutions in the fields of evaporation, separation, titration, spectroscopy AA, ICP,NIR, rheology, electrochemistry, spray dry, encapsulation, SEM microscopy, particle size, particle shape and more. Dr. Golik's team assigns specialists focused on servicing customers, needs and systems in a variety of different fields and applications. Dr. Golik operates from Tel-Aviv.

11 to 50 staff

Nrgene Ltd

NRGene applies innovative cloud-based-#genomics and data-driven insights to optimize natural resources for #foodsecurity and #sustainable #agriculture Visit our website for more information

51 to 200 staff

Curesponse

Personalized Medicine for Accurate Cancer Treatment

11 to 50 staff

Ydlabs

YDLabs provides Agri-Foodtech companies with fermentation process development and process optimization services, from lab scale to Our facilities include state-of-the-art fermenters (1-10L), 80L, 300L & as well as comprehensive purification and isolation downstream equipment. Our technical team is highly experienced, to provide fast, results-driven service so our clients are able to move forward to the next scale-up with a scalable and sustainable process. We work with companies worldwide and provide them with online data, constant updates, and consultations about their projects. Our fermentation experience and knowledge, our state-of-the-art equipment, and our excellent service have helped multiple companies accelerate their process development significantly, saving them a lot of money and time towards a successful and scalable process.

11 to 50 staff

Granalix Bio Technologies Ltd

As a startup biotechnology company, Granalix is dedicated to advancing the field of healthcare through innovation and cutting-edge research. Founded by two renowned professors, Prof. Ruth Gabizon from the Neurology Department of the Hadassah Medical Center and Prof. Shlomo Magdassi from the Casali Institute of Chemistry of The Hebrew University, Granalix represents the culmination of their combined experience and knowledge. Specializing in the development of biotechnology products, Granalix is committed to producing innovative solutions that address the most pressing healthcare challenges facing society today. The company's flagship product, Granagard, is the result of extensive research and development, and is poised to revolutionize the way we approach healthcare. As a startup, Granalix operates under the umbrella of Hadasit and Yissum, the technology transfer companies of Hadassah Medical Center and the Hebrew University of Jerusalem. This unique partnership allows the company to leverage the resources and expertise of two of the world's leading healthcare institutions, enabling it to accelerate its research and development efforts and bring new products to market more quickly. At Granalix, we are driven by a deep passion for improving healthcare outcomes and enhancing quality of life for people around the world. We are committed to pushing the boundaries of biotechnology and developing innovative solutions that have the potential to transform the field of healthcare as we know it.

11 to 50 staff

Diptera.Ai

Developing technology to fight pests with pests. Diptera's ultimate mission is to fight the spread of mosquito-borne diseases, including Zika, West Nile, Chikungunya, dengue, and malaria, by targeting the very insects that spread them. Diptera is focused on advancing methods for sex-sorting pre-adult insects, aiming to enhance techniques in controlling mosquito populations. This innovation could be pivotal in biological control strategies where only one sex, typically males, is released to suppress mosquito breeding.

11 to 50 staff

Futurx

FutuRx is a biotech incubator founded by three leading global healthcare players – Takeda (Takeda Ventures Inc.), Johnson & Johnson (JJDC), and OrbiMed Israel Partners. By combining the expertise of its management and the capabilities of its founders, FutuRx provides a unique model for the transformation of breakthrough discoveries into novel medicines. FutuRx leverages its access to the Israeli biotech industry, and to leading research institutes in Israel and worldwide, to identify and develop highly innovative technologies. Experts at Takeda, J&J, and OrbiMed are deeply involved in the project selection process and during the incubator period of each company. The result is a clear impact on the efficient translation of innovative research to clinically meaningful products.

11 to 50 staff

Matricelf

Why Matricelf? Every year, thousands of lives are forever changed by spinal cord injury (SCI)—a devastating event that strips individuals of their movement, independence, and dignity. At Matricelf, we believe this isn’t the end of the story. It’s the beginning of a new one—written by science, driven by compassion. What We Do Matricelf is a pioneering biotech company in the field of regenerative medicine, developing a curative, one-time treatment to help individuals with spinal cord injuries regain control over their lives. Our approach uses engineered human tissue, derived from a patient’s own cells, to repair damaged spinal cords—restoring not just movement, but hope. Why It Matters We’re not just growing tissue. We’re rebuilding futures. Our breakthrough holds the promise of returning the ability to walk, to work, to hug loved ones—fundamental human experiences most of us take for granted. Our Promise Still in the pre-clinical stage, Matricelf is backed by leading scientists, top-tier innovation, and a mission bigger than ourselves. We stand at the frontier of medicine, not only advancing science but rewriting what’s possible for millions. Prestige Meets Purpose Founded by world-renowned experts and recognized on global stages, Matricelf blends credibility with heart. We offer more than a treatment—we offer hope with proof, dignity with data, and a future rooted in science. Join Us Because when we restore a spinal cord, we restore a life.

11 to 50 staff

Asterix Foods

Industry leading companies like Impossible, Perfect Day (RebelBio), and EVERY (IndieBio) have shown the powerful commercial appeal of animal-free proteins. Behind this first wave comes a second wave: glycoproteins. Glycoproteins require precise glycosylations to accurately fold, recognize, and bind – driving functional performance needed in the food industry. To unlock this second wave of animal-free proteins, Asterix Foods is using plant cells, because plant cells can easily achieve glycosylations that microbial fermentation is challenged by.

1 to 10 staff

Biogencell Ltd

BioGenCell was founded with the vision of developing safe, effective, and long-lasting effective treatment for incurable, blood vessel diseases that will be both accessible and patient friendly. Our disruptive TRACT technology platform provides a comprehensive approach for rapid manufacturing and commercialization of cell-therapies.

11 to 50 staff

Breath Of Health

Breath of Health (BOH) is a cutting edge, breath-based technology offering quick, noninvasive, early detection of disease, including Covid-19. The low-cost diagnostic, which identifies over 500 particles through its proprietary AI software, has been extensively tested at renowned hospitals with proven success. Through molecular analysis, BOH is able to detect early responses in the immune system, even in the asymptomatic stages. With pre-approval from regulators including the FDA, its international patented algorithm can accurately diagnose Covid-19. The company has now begun clinical studies in five global locations. With distribution agreements with over 20 countries (awaiting FDA approval), BOH is already capable of conducting tests per day with results given within one minute or less. One of the biggest benefits of this disease-recognition system is the relative low cost of testing, offering more people a chance at early detection and improved health outcomes. Breath of Health is revolutionary in providing accessible, preventative medical testing for a range of medical conditions.

1 to 10 staff

Qrgenetics

QRGenetics is transforming the treatment of genetic diseases through GenAI-driven precision medicine. Our platform identifies and validates novel therapeutic targets by uncovering disease mechanisms in rare genetic conditions, rapidly matching them with clinically-proven, FDA-approved drugs and monitoring their validation in human trials. Leveraging these groundbreaking insights, QRGenetics then applies advanced AI analytics across extensive datasets to pinpoint similar targets in more common diseases. By partnering closely with pharmaceutical companies, we accelerate drug discovery, significantly reduce clinical risks, and bring effective treatments to broader patient populations faster. Join us on our journey to redefine precision medicine. Learn more: qrgenetics.com

1 to 10 staff

Flask Data

Flask Data is a Digital CRO. We make clinical data management simple. Flask Data is a Digital Clinical Research Organization. We specialize in executing medtech and digital therapeutics studies. Since 2019, over 10M signals, 70+ studies, 5 FDA approvals. 95% protocol compliance in neurology indications. The Flask Data Digital CRO platform helps you achieve high protocol compliance and patient retention in a flat-rate, unlimited usage monthly subscription. Challenge us. We will stand by you in good and bad times with fanatic service, straight-talk and the highest professional and ethical standards. Over 10M signals, 70+ studies, 5 FDA approvals. 95% protocol compliance in neurology indications. The Flask Data EDC Collect, Detect and Act platform helps you achieve high protocol compliance and patient retention with low headcount and high ROI. All this, in a flat-rate, unlimited usage monthly subscription. Challenge us. We will stand by you in good and bad times with fanatic service, straight-talk and the highest professional and ethical standards Our decentralized, innovative, and adaptive solutions minimize risks to clinical data, patient safety, and protocol compliance. Flas Data solutions are automated, scalable, and adaptive to the needs of each research. Flask data enables you to assure patient compliance no matter where your patients are or what device they have. Security and privacy are baked in by design by world-class Israeli cyber specialists. The Flaskdata.io platform complies with HIPAA, CCPA, GDPR, 21 CFR Part 11, and Israeli Privacy Regulations. We work with big, publicly-traded companies and three-person startups. Thousands of patients around the world and hundreds of research sites use Flask Data solutions, developed specifically for innovative companies like yours.

11 to 50 staff

Nectin Therapeutics

Nectin Therapeutics is a biotech company focused on unlocking the power of the immune system. We are developing a collection of next-generation immunotherapy agents. Despite the unprecedented efficacy of existing immunotherapy agents, many patients either fail to respond, or following encouraging initial response, develop resistance over time. At Nectin, we have discovered novel resistance mechanisms and developed novel agents targeting these mechanisms for improved therapy. At Nectin, we are dedicated to the development of novel therapeutic options for cancer patients. We are developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, we develop CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers.

1 to 10 staff

Alma Therapeutics - Oral Biologics Revolution

Alma Therapeutics is developing a novel drug delivery platform for the oral delivery of complex molecules and biologics such as: Peptides, Proteins and Antibodies

1 to 10 staff

Nanorobotics

Nanorobotics has developed a proprietary technology to target and kill cancer cells promptly via the use of Molecular NanoMachines. These tiny machines (size 1 nm) can kill the cell mechanically by drilling and tunneling through the membrane until disrupting its nucleus. We are bringing a new modality to oncology - Mechanotherapy. Our recent animal studies have shown dramatic reduction of melanoma growth that is highly resistant to immunotherapy. And the great news - our Mechanotherapy treatment is decoupled from any cancer pathogenesis, mutational rate, or tumor microenvironment. Our programmable, light-activated, nanorobots open a revolutionary new area in nanomedicine. https://nanorobotics.tech

1 to 10 staff

Newstem Ltd

NewStem is a biopharmaceutical company focused on Human Pluripotent Stem Cells (HPSCs) in general and Human Haploid Pluripotent Stem Cells (HHPSCs) in particular. These cells have the potential to change the face of medical research as they hold a pivotal role in regenerative medicine, disease therapy and cancer research. NewStem possesses pioneering intellectual property, reagents and experience related to the isolation and differentiation of HPSCs, their genetic manipulation, immunogenicity, tumorigenicity and their unique capacity in disease modeling. With this innovative research, and specialized drug and gene screening capabilities. NewStem is currently the only company worldwide to develop products based on this paradigm changing proprietary tech-nology, licensed from Yissum, Hebrew University’s technology transfer company, based on the findings and in-ventions of Prof. Nissim Benvenisty, of the Azrieli Center for Stem Cells and Genetic Research, The Hebrew University of Jerusalem.

1 to 10 staff

Sensiu By Kaizen Biotech Ltd

Nice to Meet You, We Are Kaizen! Our mission is to impact the next generation’s health by empowering nursing families. We are pioneering a new category of insight-based support for nursing families, creating two innovative breastfeeding tools designed to empower families and support lactation professionals with clear, actionable insights that enhance care. Together, we can create a future where every nursing family has the support they need to thrive.

11 to 50 staff

Immunovative Therapies Ltd

Immunovative Therapies, Ltd.(Jerusalem) and our subsidiaries, Immunovative Clinical Research, Inc.(USA) and Immunovative (Thailand) Co, Ltd.(Bangkok) is the licensor and exclusive consultant to Mirror Biologics, Inc.(Tampa) and Mirror Biologics, Ltd.(Jerusalem). As exclusive consultants, we assist and provide support to Mirror to advance our immunotherapy drug candidate,AlloStim, to commercialization. We provide drug depo management, blood donor center support, clinical site management services. In addition, we are actively collaborating with Mirror to design and build automated commercial-scale cell manufacturing pods and plug-and-play disposable sets and assisting to operate a clinical research center in Tampa and Bangkok.

1 to 10 staff

Insectprojects

InsectProjects main goal is to support companies that upscale or enter the BSF industry, by providing first-hand experience and unique skills, throughout the BSF project realization process.

1 to 10 staff

Selene Therapeutics

Selene Therapeutics is pioneering a new therapeutic strategy for treating refractory epilepsy – regulation of the neuronal activity set point by reduction of the neuronal mean firing rate (MFR).

1 to 10 staff

Circuit-Bio Ltd

Circuit-Bio is a synthetic biology company developing an innovative unique platform of logical gene circuits for cancer immunotherapy.

1 to 10 staff

Lutris Pharma

Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma’s lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and a phase 1/2 study for the treatment of radiation-induced dermatitis.

11 to 50 staff

21 West Partners

21 West Partners develops and implements momentum strategies to accelerate ad sustain the profitable growth of brands and companies. 21 West Partners acts as advisors to senior management on issues of leadership, brand strategy & communication and business development. 21 West Partners also gets involved directly as principles or partners in new ventures. Our experience is across industries but we have specific expertise in Bio-tech, Med-tech, High-Tech, Hospitality & Real Estate, Health & Wellness and Luxury Goods.

1 to 10 staff

University Of Sevilla

1 to 10 staff

Biobee Sde Eliyahu Ltd

BioBee Sde Eliyahu Ltd. is a unique company which produces beneficial insects and mites for agricultural purposes. These organisms include natural enemies for integrated biological pest control and bumblebees for natural pollination. Biological Control - BioBee's products serve both conventional and organic growers. They constitute an indispensable component in Integrated Pest Management (IPM), which aims at reducing the use of harsh chemical pesticides. IPM is at the forefront of modern agriculture and is an effective method to reduce chemical residues, and prevent the development of pesticide resistance. Biobee's products are implemented in Israel and abroad in thousands of hectares of greenhouses and open fields. Natural Pollination – BioBee produces Bombus terrestris for pollination of numerous agricultural crops including greenhouse vegetables (e.g. tomato, sweet pepper, eggplant, squash, strawberry, etc.) and open field plantations such as apple, pear, cherry, blueberry and others.

201 to 500 staff

Danyel Biotech

Danyel Biotech is a healthcare company, part of the Gamida for Life Group. This group is an interdisciplinary privately-owned group, designed to provide a focused and comprehensive service of supply and support to the Israeli scientific research community specializing in biotechnology and molecular biology, and to offer a point of contact between academic and medical research groups and their colleagues in the industrial sector.

51 to 200 staff

Seach Medical Group

Seach is an Israeli based medical Cannabis group focused on growing, developing and producing top-grade medical Cannabis products and technologies. In 2002, Seach was the first group to apply for an Israeli license to grow Cannabis for medical purposes. In 2005 Seach was granted the first commercial growing license from the Israeli Minister of Health ("MOH") to serve patients in Israel. Seach started as a small family-based operation, supplying Medical Cannabis to Israeli MOH and directly to patients. Seach, is an outgrowth of a 60 year old, large Israeli floriculture farm. The four founders of Seach have over 50 years of experience in agriculture industry and over 10 years of experience in Medical Cannabis Industry and are personally involved in every ongoing project, as well as the planning of future endeavors. Seach evolved to be one of the leading Medical Cannabis growers and suppliers in Israel, breeding, growing and supplying top grade medical Cannabis to Hospitals, Clinical Trials and Patients. We are deeply involved in Cannabis related medical research, clinical trials and development of a wide range of Cannabis oriented technologies in our technology incubator. Seach is a member of the Israeli Cannabis Growers Association, and held the position of Chairman for 2 years.

51 to 200 staff

Origene Seeds

ORIGENE SEEDS is an innovative international seed company, active in research, plant breeding, seed production and processing, sales & marketing of hybrid vegetable varieties. The company's strategy is to develop new hybrids with novel traits of quality, taste, flavor, uniformity, high nutrition values, shelf life, all combined with high yield and environmental friendly. The hybrid varieties are suitable for the commercial outdoor crops or greenhouse growers as well for plant raisers, for the professional sectors. Our company breeds vegetables for markets in more than 25 countries.

51 to 200 staff

Profuse Technology

ProFuse is the skeletal muscle growth expert, developing innovative therapies for skeletal muscle loss and products for cultivated meat production. Addressing the critical unmet need for effective drugs for muscle-wasting diseases, ProFuse leverages its proprietary technological assets to efficiently and accurately discover novel muscle therapies. Our platform enables the high-throughput screening of thousands of compounds, identifying promising candidates with a high translational potential. For the cultivated meat industry, we sell cutting-edge products- cell lines and differentiation media supplements to significantly reduce costs, enhance muscle growth, increase yield and accelerate production cycles. ProFuse actively collaborates with leading companies seamlessly integrating our products and knowhow into their production processes. Founded in 2021, ProFuse licensed technology developed over four years of research at the Weizmann Institute of Science. Since then, we have achieved significant milestones, including winning first place in the 2021 Israel FoodTech Startup Competition and securing exclusive grants from both the European Innovation Council and the Israel Innovation Authority. We have launched two product lines and are actively supporting our cultivated meat customers in their scale-up efforts. We are particularly proud of our R&D team's focus on skeletal muscle biology which is strengthened by the expertise of Professors Eldad Tzahor (Weizmann Institute of Science, Israel) and Professor Shulamit Levenberg (Technion, Israel).

11 to 50 staff

Orgenesis Biotech Israel Ltd

Orgenesis Biotech Israel LTD, a subsidiary of Orgenesis Inc, is a specialized process and product development firm focused on custom-made process development, upscaling design from lab to industry innovation and automation procedures, which are extremely essential in the cell therapy industry. The company is located in Bar-Lev Industrial Park utilizing the exclusive Israeli innovative ecosystem and highly experienced and talented associates including Ph.D. holders and Biotechnology engineers. The center provides end to end solutions to cell therapy industries, process development capabilities and proficiency, custom-made engineering, and a unique platform for creative design and process optimization. The company spreads over 1300 sqm2 of labs and offices resulting in an efficient and unique environment for cell therapy development.

11 to 50 staff

A2s Technologies Ltd

A2S technologies Ltd is a trading Biotech supplier company distributing in Israel leading biotech manufacturer. we are specialized in laboratory equipment, with over 15 years experience in the field. We supply products and services to the Biotech, Biopharma, Pharmaceutical, Research institutes, universities and Hospitals. With our "Consulting & Sales" and "Technical Service", we are able to respond to your requests and needs the most accurate when it comes to laboratory equipment. Our collaboration closely linked with our suppliers allows us to be aware at every moment for news and technical specialties. Flexibility is our strength! We offer personalized services tailored to your needs. Try us! Do not hesitate to contact us for any new project planning, equipment or consumables, we seek the best solution and submit you a free quote without obligation on your part.

1 to 10 staff

Huminn

Huminn Convergence Innovation™ operates on the principle that nature is an interdependent and complex system in order to benefit the entire network and not just its separate domains Convergence Innovation™ Uniquely integrated Platform: Huminn is an innovations company at the forefront of science and technology. Working with leading, interdisciplinary scientists, Huminn deploys cutting-edge precision molecular biology tools with proprietary and novel statistical rediction algorithms to create and commercialize visionary integrated solutions to critical global challenges in health, wellness and sustainable development Huminn connects dots - Others compartmentalize. Huminn connects dots. Others see problems. Huminn marries new tech, new thinking, and a new cast of collaborators to create sustainable solutions that have signicant positive economic, environmental and cultural impact

11 to 50 staff

Neotx Therapeutics Ltd

NeoTX is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy. With a strong research and development team, our strategy is to build a patented, proprietary and unique product pipeline to capitalize on technologies that NeoTX is developing independently and through collaborative partnerships and license agreements.

11 to 50 staff

Sequentify

At Sequentify, we empower genomic labs to achieve scalable, population-wide genomic sequencing through our innovative solutions. Our technology is designed to decentralize genomic testing by addressing the industry's top three challenges: sample preparation, result analysis, and cost reduction. Our end-to-end solution offers unmatched scalability, automation friendliness, and cost-effectiveness, making it ideal for diverse applications, including cancer diagnostics, carrier screening, and infectious disease. Currently raising our Series A round, as we aim to accelerate growth.

11 to 50 staff

Biological Industries Sartorius

BIOLOGICAL INDUSTRIES (BI) develops, manufactures and supplies life science products to universities, government research and healthcare institutions and to the bio-pharmaceutical industry. With an in-house R&D Department and over 30 years of experience, as well as through know-how collaborations with academic researchers, we have introduced a series of serum-free media and many other products for animal tissue culture and molecular biology. In recent years, we have developed NutriStem®- a serum-free, xeno-free gold standard media advancing the fields of stem cell-based therapies. BI manufactures in a cGMP compliant facility that consists of ISO 5, 7 and 8 clean rooms, and holds ISO 13485:2003 and ISO 9001:2008 certifications. We are committed to a Culture of Excellence through high quality, cost-effective and innovative products and services, tailored to our customer's specific needs. Locations include the USA, Europe, China and Israel.

51 to 200 staff

Imbh - For Life Science

Proven products. Reliable service. Expert consultation. For decades, researchers have relied on our media, cell cultures, reagents, and kits for their laboratories. Our proven products and equipment are sourced from leading companies for use in cell culture & analysis, protein analysis, and more. Working closely with our customers, our handpicked team devises custom solutions for cell authentication and cell bank production and specialized kits and reagents to help researchers achieve the results they want.

11 to 50 staff

Longevity Ai

Transform your practice's clinical and lifestyle data into personalized, evidence based longevity plans - automatically.

11 to 50 staff

Nibn The National Institute For Biotechnology In The Negev

The National Institute for Biotechnology in the Negev Ltd. is a research Institute that serves as an accelerator for technologies originating from Ben-Gurion University of the Negev, and located in the University campus. The institute's goal is to promote applied, innovative and groundbreaking research in the field of biotechnology, while leading the proof of scientific concept and commercialization. The research at the Institute focuses on areas that are at the forefront of the development of the pharma industry: Cancer, Degenerative diseases, Autoimmune and Metabolic diseases, Infectious diseases, Genetic diseases, as well as, applied Biotechnological research in the fields of AgBio. The research at the Institute has yielded over 900 publications in leading scientific journals, more than 60 patent families and a number of commercializations, mainly, licensing breakthrough technologies to third parties for further development and as a basis for establishing new startups.

51 to 200 staff

Plantarcbio

PlantArcBio Ltd.(TASE:PLNT) is an ag-biotech company developing gene discovery and RNAi-based solutions to enhance crop traits and biologically control pests, with a vision to improve global food security and promote sustainable agriculture. With our patented DIP™ and DIPPER™ technologies, we discover and develop novel genes and gene-editing targets, as well as support gene editing processes, with game-changing effects on plants — including yield improvement, drought resistance, herbicide tolerance, and nutritional enhancement. Genes identified through the DIP™ platform enable seed companies to enhance a variety of crops with desired traits more effectively than ever before. For example, PlantArcBio partnered with seed company Rallis to develop drought-tolerant corn, demonstrating a 60%–250% yield increase under drought conditions. Our DIP™ and DIPPER™ platforms, along with the novel genes and RNAi targets we have discovered and developed, are protected by patents at various stages of registration. We have signed multiple partnerships with leading seed and crop protection companies to enhance crops with drought resistance, increased yield, herbicide tolerance, and insect resistance. We are seeking additional partners to introduce our novel genetic technologies and further improve crop performance. Our RNAi developments focus on external applications and integrated solutions for crop protection and yield enhancement. Our deep expertise and innovative RNAi technologies, combined with a unique methodology for identifying target gene sequences, make us a strong partner for co-developing next-generation RNAi pest control solutions. PlantArcBio's global strategic partners include ICL, Gadot-Agro, KWS, CTC (Brazil), TMG (Brazil), Bioceres (Argentina), Rallis (a subsidiary of TATA, India), Toolgen (Korea) and others.

11 to 50 staff

Scivac Limited

SciVac Ltd, a subsidiary of VBI Vaccines Inc.(Nasdaq: VBIV), has the facilities and expertise that enable development of therapeutic proteins starting with a selected clone, through production, purification, and analytical testing. For your phase I and II clinical trials, SciVac Ltd. offers manufacturing services under cGMP conditions.

11 to 50 staff

Hallura

Breaking with 20-year-old technologies and answering the growing demand for natural and soft aesthetic treatments, HALLURA is reinventing Hyaluronic Acid Dermal Fillers

1 to 10 staff

Ela Pharma Ltd

Ela Pharma is driven to create novel therapeutics for better patient recovery and care, in the most pressing clinical applications such as organ preservation, retinal artery occlusion, acute ischemic conditions and acute liver failure. Our proprietary technology is based on small molecules to inhibit intracellular proteolytic enzymes targeting novel anti-necrotic based pathways.

1 to 10 staff

Liposphere Ltd

Liposphere is a biomedical start-up company spun out from the Weizmann Institute of Science (Israel) in 2019. The Company develops highly lubricious, water-based, biocompatible nanomaterials for conditions of the human body, where ultralow friction is of utmost importance. The team has spent over 10 years on basic academic research and development of the compound at the Weizmann Institute before spinning out the technology. LipOsphere’s technological advantage, based on the discovery of the Hydration Lubrication Mechanism, is worldwide IP protected.

11 to 50 staff

Opko Biologics Ltd

OPKO Biologics Ltd.(formerly Prolor Biotech), a subsidiary of OPKO Health Inc, is a clinical stage company developing next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs, utilizing CTP and reversible PEGylation technologies. The CTP technology involves fusing one or more copies of a naturally occurring glycosylated peptide by rDNA technology to the protein chain ends. When attached to a therapeutic protein, CTP significantly extends its longevity in the body. OPKO Biologics’ second technology is reversible PEGylation, a synthetic chemistry-based platform for enhancing the half-life of therapeutic peptides and small molecules. Using a hydrolysable linker bypasses the disadvantages of using a standard PEGylated molecule, i.e. the potential for steric hindrance that limits its function, and the limited ability to cross cellular membranes or the blood-brain barrier. OPKO Biologics currently presents two bio-better long-acting products: hGH-CTP (Somatrogon, MOD-4023): CTP-modified human growth hormone (hGH). OPKO completed a pivotal Phase 3 study in growth hormone-deficient (GHD) adults and is currently conducting a Phase 3 study in a GHD pediatric population. The company completed a Phase 2 study in GHD adults, demonstrating that a single weekly injection of hGH-CTP could potentially substitute seven consecutive daily injections of regular hGH, and showing an excellent safety profile. OPK88005: CTP-modified long-acting coagulation factor VIIa, potentiality supporting every-other-day prophylactic treatment or twice a week regimen in hemophilia patients. OPK88005 is currently evaluated in an ongoing Phase 2a clinical study.

51 to 200 staff

Lifegene - People Connecting Science

At LifeGene we believe in making the difference, we are an eco-friendly company with a dynamic style and a creative approach. We are committed to focusing on the needs of our customers and to providing service of the highest quality. Our aim is to be a part of our customers' success and to follow them and support them in their breakthroughs in life science research.

1 to 10 staff

Transalgae

Microalgae based oral delivery platform

11 to 50 staff

Caleetech

CaleeTech is a biotech startup specializing in providing novel solutions for obesity and diabetes (diabesity). CaleeTech will improve diabetic parameters and weight management by significantly reducing calory absorption, blood sugar, and fat level without compromising on the patient's quality of life. CaleeTech product is unique, has a high safety profile, is transient and can be used repeatedly. It also addresses market trends – as a quick solution, easy to use, based on natural ingredients and affordable. It was extensively tested on bench and in-vivo with successful recovery and histopathological studies. A clear regulatory strategy is in place after productive meetings with the FDA, and Phase 1 successful clinical trial performed in 2023 in a RAMBAM, diabetes department.

1 to 10 staff